"The rapid issuance of this first PreDx patent reflects the company's commitment to an intellectual property portfolio that will support its rapid commercialization of novel technology to identify patients at risk of developing type 2 diabetes and other chronic cardiometabolic diseases," said Mickey S. Urdea, Ph.D., Tethys chairman and chief executive officer. "The cost of treating all patients at risk for diabetes is not sustainable and threatens to break the U.S. healthcare system. We believe that the direct impact of PreDx DRS will be to mitigate the type 2 diabetes epidemic and lower healthcare costs by providing physicians with a powerful tool that will enable them to focus preemptive interventions on patients most at risk of developing the disease."

Diabetes represents the largest pandemic in history: 171 million people worldwide have diabetes with hundreds of millions more at risk. Diabetes is, however, preventable. PreDx DRS offers a simple-to-use, accurate, validated tool to identify patients at imminent risk of developing chronic cardiometabolic disease while there is still time to forestall disease progression.

SOURCE Tethys Bioscience, Inc.,